Duke University oncologist Amy Abernathy says the policy shift towards more comparative effectiveness research presents some problems for researchers doing work in cancer, reports Scientific American's Katherine Harmon. The first problem, Harmon writes in the Observations blog, is that comparative effectiveness research focuses on broad populations of patients, but that oncology is about individual treatment.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.